Analysts predict that Genomic Health, Inc. (NASDAQ:GHDX) will report sales of $112.63 million for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Genomic Health’s earnings, with the lowest sales estimate coming in at $111.60 million and the highest estimate coming in at $114.23 million. Genomic Health reported sales of $101.26 million during the same quarter last year, which indicates a positive year over year growth rate of 11.2%. The firm is scheduled to issue its next earnings results on Tuesday, November 5th.

On average, analysts expect that Genomic Health will report full-year sales of $450.27 million for the current year, with estimates ranging from $446.30 million to $452.03 million. For the next year, analysts forecast that the business will post sales of $494.62 million, with estimates ranging from $484.00 million to $504.81 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.07. The firm had revenue of $114.14 million during the quarter, compared to analyst estimates of $110.78 million. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The business’s revenue was up 19.4% on a year-over-year basis. During the same quarter last year, the business earned $0.23 EPS.

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC lowered shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. BidaskClub raised shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 6th. Deutsche Bank dropped their price objective on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating for the company in a report on Thursday, May 30th. Canaccord Genuity lowered shares of Genomic Health from a “buy” rating to a “hold” rating and dropped their price objective for the company from $77.00 to $72.00 in a report on Tuesday, July 30th. Finally, Zacks Investment Research raised shares of Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 target price on the stock in a research report on Wednesday, July 31st. Nine investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $69.86.

Shares of Genomic Health stock traded up $0.49 during trading on Friday, hitting $74.35. The stock had a trading volume of 125,912 shares, compared to its average volume of 574,076. The firm’s fifty day simple moving average is $65.95 and its 200-day simple moving average is $65.80. The stock has a market cap of $2.77 billion, a PE ratio of 70.81 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.74 and a quick ratio of 5.74. Genomic Health has a 12 month low of $50.77 and a 12 month high of $92.18.

In related news, insider Jason W. Radford sold 2,181 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $74.13, for a total transaction of $161,677.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Frederic Pla sold 1,251 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $75.00, for a total value of $93,825.00. The disclosure for this sale can be found here. Insiders sold 429,033 shares of company stock worth $29,008,299 in the last ninety days. 31.30% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of GHDX. DekaBank Deutsche Girozentrale lifted its holdings in Genomic Health by 2.9% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,000 shares of the medical research company’s stock worth $394,000 after acquiring an additional 200 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in Genomic Health by 12.7% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,301 shares of the medical research company’s stock valued at $192,000 after purchasing an additional 372 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Genomic Health by 29.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 441 shares during the period. LPL Financial LLC lifted its position in Genomic Health by 11.1% during the second quarter. LPL Financial LLC now owns 4,820 shares of the medical research company’s stock valued at $280,000 after purchasing an additional 483 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its position in Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 493 shares during the period. 94.48% of the stock is owned by hedge funds and other institutional investors.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.